Injectable semaglutide at equivalent therapeutic doses (2.4mg weekly Wegovy) produces average weight loss of 14.9% over 68 weeks in clinical trials
Earlier this week, the company Hims, arguably the best-known source of compounded GLP-1s, announced that it would stop marketing these drugs as part of a truce formed with Novo Nordisk
Do not self-administer retatrutide based on this chart
Among patients who previously used a GLP-1-based medication, most switched from injectable anti-obesity medications (AOM), including injectable AOM semaglutide (sold as Wegovy) and AOM tirzepatide (sold as Zepbound)
According to Cleveland Clinic, medications that act on GLP-1 approved by the U.S
High-fat, greasy, and fried foods significantly worsen nausea and GI side effects on GLP-1 medications